COMMITTEE OF EXPERTS
WHY A COMMITTEE ADVISOR ?
The committee of experts The expert panel, together with the project selection panel committee , will function as a body independent of the projects and will provide advice on an ad hoc basis and on demand by the incubator's managers. Among the objectives of the committee objectives of the committee include: to keep abreast of global trends in the field of health, to provide the project with international visibility and to expand the network contacts of the project in those centers and companies over which the experts have some influence subject .
Cupertino, California. Of Indian origin, he is a telecommunications engineer. Serial Entrepreneur linked to medtech companies, having sold some of them to big pharma like Roche. He is very involved in the fight against cancer by applying AI/ML, is launching his business INDX and offering partnership to the CUN /CIMA. He teaches "innovation affordable" at Stanford University.
Founder of Oncomatryx. Creation in 2000 of Progenika Biopharma, S.A. The companies of group Progenika are pioneers in the development, production and commercialization of molecular diagnostic and clinical therapy systems based on Genomics and Proteomics tools. Relationships with numerous pharmaceutical companies. advisor in different scientific committees of public institutions and private foundations. Numerous articles in high impact scientific journals and several awards, including the award Eurowards European Entrepreneur, in 2004, the award Ernst & Young most innovative entrepreneur of the year, in 2010 and Ruban d'honneur of the European Business Awards - HSBC Bank, in 2011.
Medicine from the UN (1979) and specialist in Cardiology from the CUN. Subsequently he was a cardiologist in several public and private institutions, with emphasis on non-invasive cardiology techniques and intensive care. Entrepreneur and expert in medtech.
MBA from IE, with more than 30 years in the medical device industry. management profit and loss, management sales of direct sales teams and distributors, management talent, medical affairs and management opinion leaders core topic (KOL), market access and development market, strategic planning for new product launches and geographic expansion.
Jesús M. Hernández has 30 years of experience in leadership positions in pharma and biotechnology, and in finding academic drug and technology transfer.
He worked 20 years at Eli Lilly and Company, where he started his degree program as a clinical research physician, moving soon to the management scale and occupying different executive positions in the Spanish subsidiary and in the European Management team as Director Executive of research Clinical and Regulatory Affairs, and as Vice President of Medical Affairs, for Europe.
In 2010 he moved to the research center Applied Medical (CIMA) of the University of Navarra, Spain, where he served as director general and fostered the goal translational research of CIMA. He was CEO of Digna Biotech, member of the Boards of Hepacyl Therapeutics, Formune Vaccines and Vivet Therapeutics, all CIMA startups. He was one of the main drivers of the agreement between CIMA and Vivet Therapeutics ─based gene therapy licenses from CIMA─'s research , helping to raise €37.5 million, possibly one of the largest Series A rounds for a business with licence Spanish biotech.
He holds an MD and a PhD in Medicine, and is a specialist in Infectious Diseases. He attended several executive programs at IESE Business School (PADE 2010), Harvard Business School, Harvard Medical School, INSEAD and London Business School (ADP28), and is visiting professor at the University of Navarra, Spain.